NEW YORK(GenomeWeb) – Proteomics firm Caprion said today that it has signed an agreement to license Integrated Diagnostics' Xpresys Lung cancer test.

The agreement gives Caprion exclusive rights to market and commercialize Xpresys Lung in Canada.

Xpresys is intended to aid doctors in identifying lung nodules detected via CT scans as likely benign. The test uses multiple-reaction monitoring mass spec to quantify the levels of 11 proteins in patient blood samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.